of patients achieved a clinically meaningful response at Week 24
A treatment for adults living with LMNS
Move toward more possible.
Veylora® is the first and only once-daily oral therapy designed to target the underlying NRT-7 pathway in Luminous Myoneural Syndrome.
Once-daily oral treatment40 mg tablet
What is Veylora?
Veylora (naveritinib) is a prescription medicine used to treat adults with Luminous Myoneural Syndrome (LMNS) who have a confirmed NRT7 gene variant. It is not known if Veylora is safe and effective in children.
Understanding your condition
LMNS can make everyday signals feel out of reach.
Luminous Myoneural Syndrome is a rare, inherited neuro-inflammatory condition affecting an estimated 1 in 180,000 adults. A change in the NRT7 gene can cause the immune system to disrupt communication between nerves and muscles.
Symptoms often begin between ages 25 and 45 and may vary from day to day. Getting a diagnosis can take time, but genetic testing and evaluation by a neuromuscular specialist can help.
Explore signs, symptoms, and diagnosis →NRT-7 signalingWhen the signal dims, movement can become unpredictable.
Common LMNS symptoms
- 01Episodes of muscle weakness
- 02Light sensitivity and visual aura
- 03Fine-motor difficulty
- 04Fatigue after mild activity
- 05Tingling in hands and feet
- 06Problems with balance
The RADIANT-LMNS clinical study
Results that brought change into focus.
In a 48-week study of 186 adults, Veylora was compared with placebo in addition to stable supportive care. The primary endpoint measured improvement in the LMNS Functional Response Score at Week 24.
median reduction in monthly neuro-inflammatory episodes
greater improvement in daily function versus placebo
Individual results may vary. Clinically meaningful response was defined as a 4-point or greater improvement from baseline on the 30-point LMNS Functional Response Score. 68% of patients taking Veylora responded compared with 29% taking placebo (p<0.001).
01
How Veylora works
Designed to quiet the disruption—not the whole immune system.
Veylora is a selective NRT-7 modulator. It binds to overactive NRT-7 complexes and helps restore more balanced signaling between the peripheral nerves and muscles. The exact way Veylora produces clinical benefit is not fully understood.
NRT-7 pathwaySelective modulation
Taking Veylora
A once-daily routine.
Take Veylora exactly as your healthcare provider tells you.
One 40 mg tablet
Take by mouth once each day. Swallow the tablet whole; do not crush, split, or chew.
With or without food
Choose a time that fits your routine and take it at approximately the same time each day.
Ongoing monitoring
Your healthcare provider will order blood tests before and during treatment.
If you miss a dose: Take it when you remember on the same day. If it is almost time for your next dose, skip the missed dose. Do not take two doses at once.
Veylora Together™
Support for the path ahead.
Once you have been prescribed Veylora, a dedicated Care Navigator can help you understand insurance coverage, explore financial assistance, coordinate delivery, and stay connected throughout treatment.
Call 1-844-VEY-LORAMonday–Friday, 8 AM–8 PM ET
One-on-one help from enrollment through treatment.
*Eligibility restrictions and annual maximums apply. This fictional program is not valid for prescriptions reimbursed under Medicare, Medicaid, or other federal or state healthcare programs.
Helpful resources
Knowledge for your next step.
Download tools created for patients and care partners.
Starting Veylora
A plain-language guide to treatment, monitoring, and support.
Read more →Talk with your specialist
Questions to help make the most of your next appointment.
Read more →Supporting someone with LMNS
Practical ideas for care partners and families.
Read more →Important Safety Information
What is the most important information I should know about Veylora?
Veylora may cause serious side effects, including:
Serious infections. Veylora can lower the ability of your immune system to fight infections. Serious and sometimes fatal infections have occurred. Your healthcare provider should test you for tuberculosis and hepatitis before treatment. Tell your healthcare provider right away if you develop fever, chills, cough, shortness of breath, painful urination, or sores.
Liver problems. Increased liver enzymes have occurred. Your healthcare provider will perform blood tests before and during treatment. Tell them right away about yellowing of the skin or eyes, dark urine, nausea, vomiting, upper-right stomach pain, or unusual tiredness.
Blood clots. Blood clots in the legs or lungs may occur. Get emergency help for sudden shortness of breath, chest pain, or swelling, pain, or tenderness in a leg.
Do not take Veylora if you:
- have an active serious infection.
- have had a severe allergic reaction to naveritinib or any ingredient in Veylora.
Before taking Veylora, tell your healthcare provider about all medical conditions, including if you:
- have an infection, liver problems, or a history of blood clots.
- recently received or plan to receive a vaccine. Avoid live vaccines during treatment.
- are pregnant or plan to become pregnant. Veylora may harm an unborn baby. Use effective birth control during treatment and for 4 weeks after the last dose.
- are breastfeeding. Do not breastfeed during treatment and for 1 week after the last dose.
What are the most common side effects?
The most common side effects of Veylora are upper respiratory tract infection, headache, nausea, increased liver enzymes, diarrhea, and tiredness. These are not all possible side effects. Call your healthcare provider for medical advice about side effects.
Tell your healthcare provider about all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Strong CYP3A inhibitors or inducers may affect how Veylora works.
Read complete safety information →
This website is a fictional demonstration. Veylora, naveritinib, LMNS, the clinical trial, and all safety and efficacy claims are invented and must not be used for medical decision-making.